Publicaciones en las que colabora con Juan María González Lahoz (32)

2010

  1. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 7, pp. 1486-1492

2009

  1. Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 10, pp. 4153-4158

2008

  1. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir

    Clinical Infectious Diseases, Vol. 46, Núm. 11, pp. 1782-1785

  2. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 1, pp. 200-205

  3. Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 3, pp. 694-698

  4. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 816-822

2007

  1. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 7, pp. 879-885

  2. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241

  3. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients

    Antiviral Therapy, Vol. 12, Núm. 4, pp. 459-468

  4. Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy

    AIDS, Vol. 21, Núm. 5, pp. 583-588

  5. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy

    Journal of Medical Virology, Vol. 79, Núm. 8, pp. 1040-1046

  6. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors

    Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 4, pp. 885-888

  7. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors [6]

    Journal of Antimicrobial Chemotherapy

2006

  1. Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy

    Journal of Acquired Immune Deficiency Syndromes, Vol. 43, Núm. 3, pp. 324-326

  2. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients

    AIDS Research and Human Retroviruses, Vol. 22, Núm. 12, pp. 1231-1235

2005

  1. Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin

    Antiviral Therapy, Vol. 10, Núm. 4, pp. 557-561

  2. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection

    Journal of Medical Virology, Vol. 76, Núm. 1, pp. 1-6

  3. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption

    Clinical Infectious Diseases, Vol. 41, Núm. 6, pp. 897-900

2004

  1. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy

    AIDS Research and Human Retroviruses, Vol. 20, Núm. 3, pp. 271-273

  2. Impact of Drug Levels and Baseline Genotype and Phenotype on the Virologic Response to Amprenavir/Ritonavir-Based Salvage Regimens

    AIDS Patient Care and STDs, Vol. 18, Núm. 1, pp. 1-6